Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PAVR: High-Resolution Cellular Imaging via a Physics-Aware Volumetric Reconstruction Framework.

bioRxiv : the preprint server for biology·2026
Same author

High-throughput Genome Wide CRISPR Knock Out mechanical sort identifies genes driving metastatic cancer cell softening.

bioRxiv : the preprint server for biology·2026
Same author

Lipid nanoparticle GM-CSF replacement for autoimmune pulmonary alveolar proteinosis.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Tumor agnostic drug delivery with dynamic nanohydrogels.

Nature communications·2026
Same author

Barriers to the Pharmacologic Rescue of W1282X CFTR.

Biochemistry·2025
Same author

Glycolipid nanoparticles target the spleen and detarget the liver without charge.

Proceedings of the National Academy of Sciences of the United States of America·2025

Related Experiment Video

Updated: Jun 29, 2025

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.1K

Nucleic acid-based drugs for patients with solid tumours.

Sebastian G Huayamares1,2, David Loughrey1,2, Hyejin Kim1,2

  • 1Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.

Nature Reviews. Clinical Oncology
|April 8, 2024
PubMed
Summary

Novel nucleic acid therapies, including gene therapies and mRNA nanoparticles, show promise for treating advanced solid tumors. These treatments offer new hope for patients with refractory cancers, alone or with standard care.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.5K

Related Experiment Videos

Last Updated: Jun 29, 2025

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Advanced-stage solid tumors often resist conventional multimodality treatments (surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy).
  • Nucleic acid-based drugs are emerging as potent therapeutic options for refractory tumors.

Purpose of the Study:

  • To review the development and clinical activity of viral and non-viral nucleic acid-based treatments for solid tumors.
  • To discuss mechanisms of action, tolerability, efficacy, and the impact of the tumor microenvironment on drug delivery.
  • To highlight future trends, clinical trial outcomes, and manufacturing considerations for next-generation nucleic acid agents.

Main Methods:

  • Review of existing literature on viral vectors (gene therapies) and non-viral nucleic acid therapies (mRNA, other nucleotides).
  • Analysis of clinical activity, mechanisms of action, tolerability, and efficacy data from solid tumor patients.
  • Examination of the tumor microenvironment's influence on systemic and local drug delivery.

Main Results:

  • Viral and non-viral nucleic acid therapies demonstrate potential in treating advanced solid tumors, including refractory cases.
  • Approved gene therapies and emerging nanoparticle-based treatments are expanding therapeutic options.
  • Tumor microenvironment significantly affects drug delivery and therapeutic outcomes.

Conclusions:

  • Nucleic acid-based drugs represent a significant advancement in oncology, offering new avenues for patients with limited treatment options.
  • Ongoing research and development are crucial for optimizing delivery, efficacy, and manufacturing of these novel therapies.
  • Future nucleic acid agents are expected to further improve outcomes for solid tumor patients.